Why Lung Cancer Vaccines Are Worth Watching
October 27, 2026
You may have seen recent news about one of the most hopeful storylines in cancer research from an unexpected place: Melanoma (a type of skin cancer).
Results from a study pairing a personalized cancer vaccine with an existing immunotherapy drug suggest that people with high-risk melanoma who received the combination were meaningfully less likely to have their cancer return than those who received the standard drug alone. This finding has generated real excitement, as it is the first time a personalized treatment, tested in a large, late-stage clinical trial, has clearly shown a cancer vaccine can keep more people cancer-free (meaning the cancer doesn't come back or spread to other parts of the body) than the current standard of care alone.
Naturally, people living with lung cancer want to know if it could help them.
The honest answer: Possibly. But we are not there yet.
Lung cancer vaccines are being actively studied in both major types of the disease, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), but they have a history of falling short. What has changed is not simply renewed enthusiasm, but new technologies and a much better understanding of why earlier attempts fell short. Let’s look at where things stand today, the approaches currently being studied, and questions worth bringing to your next oncology visit.
What is a therapeutic cancer vaccine?
Note: Several names describe treatments with a similar mechanism to fight lung cancer. Here, we'll use the umbrella term "therapeutic cancer vaccines" or simply “cancer vaccines.”
Most people think of vaccines as something used to prevent an infection. The core concept is simple. Your immune system is very good at spotting and destroying things that look foreign. So, a flu shot, for example, teaches it to better recognize the flu virus before you ever encounter it.
Cancer vaccines build on the same concept but take it in a different direction. Most cancer vaccines being studied in lung cancer are “therapeutic vaccines,” meaning they are given to people who already have cancer, with the goal of treating it or preventing its return.
Because cancer cells arise from healthy cells, they can look almost normal, making them harder for your immune system to detect. To help, researchers have identified specific markers called “neoantigens” found only in or on cancer cells. A therapeutic cancer vaccine trains immune cells to identify these neoantigens by showing them a specific neoantigen (or sometimes several) found on the cancer, so they learn to target and destroy any cell expressing them.
The approach hinges on 2 questions: Which targets do you teach the immune system to recognize, and how do you deliver that information?
The different strategies being explored
Researchers are pursuing several strategies for the "which targets" question, which truly separates one vaccine approach from another:
- Personalized neoantigen vaccines. Every person's tumor carries its own unique set of mutations. This approach identifies neoantigens found only in an individual’s specific tumor and builds a one-of-a-kind vaccine for that person. It is the most customized approach, and the one most closely related to the melanoma research making headlines, but each vaccine must be manufactured from scratch, which takes time and resources.
- Shared "off-the-shelf" neoantigen vaccines. These target neoantigens common across many individuals’ lung cancers. Because they aren’t built for each person, they can be produced in bulk and given more quickly, though the match to each person’s tumor is somewhat less precise.
- Single-target neoantigen vaccines. A narrower version of the “off-the-shelf” idea, these focus on one highly specific neoantigen broadly overexpressed across a cancer type (or multiple cancer types), rather than a panel of several.
- Vaccines aimed at the tumor's defenses. Rather than targeting the cancer cell directly, these teach the immune system to attack the cells and/or molecules the tumor uses to hide from or suppress the immune response.
- Growth-signal–depleting approaches. A different strategy altogether, these teach the body to stop (or prevent) signals telling lung cancer cells to keep dividing, effectively “starving” the cancer of a "keep growing" message rather than marking cells for direct killing.
Regardless of strategy, another important factor is how the target signal is delivered to the body. This is called the vaccine platform.
Some platforms use genetic information, such as mRNA or DNA, that tells your own cells to briefly display the selected neoantigen(s) for immune cells to learn from. The mRNA platform is the same technology many people became familiar with during the COVID-19 pandemic and is the one used in the melanoma headlines. Others deliver the neoantigen as a ready-made protein or protein fragment, use a harmless virus as a delivery vehicle, or take a person’s own immune cells out of the body, “educate” them, and return them to the body.
Platforms differ in the strength and durability of the immune response they produce, and the same neoantigen can sometimes be delivered by more than one platform.
Why is this so challenging, and what do we still not know?
In earlier trials, vaccines often did exactly what they were designed to do in a narrow sense. Blood tests showed immune systems learned to recognize the target neoantigen, but people didn’t live longer. We now understand this is at least partly related to the environment surrounding the tumor.
Cancer is not just a lump of cells. Tumors build a protective environment that actively blocks, exhausts, and switches off incoming immune cells. Addressing this can greatly affect the outcomes of the therapy being tested.
A second, related lesson is that vaccines consistently perform worse in advanced, widespread disease, where tumor burden (the overall amount of cancer in the body) is high, and the cancer's defenses are most entrenched. Cancer vaccines have generally looked more promising in earlier-stage disease, or after surgery has removed the main tumor and the goal is to clear small amounts of remaining cancer cells. Newer studies deliberately focus on these lower-burden settings, which may lead to different outcomes than we’ve seen before.
Other questions require further study, such as:
- Do vaccine responses mean people with cancer will live longer?
- Which patients benefit most? How long does protection last?
- How are these vaccines best combined with existing treatments?
These and other questions will hopefully be answered by current and future studies.
Questions for your oncologist
If cancer vaccines interest you as a treatment option, the following questions may help you have a focused, productive conversation with your healthcare team.
- Given my specific type and stage of lung cancer, might I be eligible for a vaccine study?
- Are there vaccine clinical trials open at this center, or at one you could refer me to?
- Would a cancer vaccine be studied alone or combined with other treatments I might otherwise receive?
- What would a clinical trial involve in terms of visits, procedures, and time?
- If a trial isn't a good fit right now, what treatment(s) would you recommend instead? Could a trial become an option later?
The bottom line
Cancer vaccines have moved from a dream to one of the most promising frontiers in cancer care, and the recent melanoma results are a large part of why.
For lung cancer, optimism is real but should be held alongside an honest view of the previous track record. Newer technologies and smarter study design build directly on past lessons in hopes of a brighter future, one that is being watched closely.
For now, the most important step for anyone interested in cancer vaccines as a treatment option is to ask their oncologist whether a clinical trial is a fit.
If you have more questions about lung cancer vaccines, or questions about treatment, trials, or biomarker testing, you may also speak with our LungMATCH team by emailing support@go2.org or calling 1-800-298-2436.